To address this escalating health crisis, current DKD management emphasizes four core pharmacologic classes: renin–angiotensin–aldosterone system inhibitors (RAASi), mineralocorticoid receptor antagonists (MRAs), sodium–glucose co-transporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) (5). This evidence concerns the gene GLP1R and diabetic kidney disease.